AL
ALTME.PA TME Pharma N.V.
- Market cap
- EUR 10.4M
- P/E
- -
- P/B
- 6.15x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALTME.PA undervalued?
Graham numberThe Graham number of TME Pharma N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TME Pharma N.V. fundamental analysis
2 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-933.21%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-288.94%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 2/2
The stock has a minimal amount of debt (-321%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Net Profit Growth 0/2
This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 0/1
The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.
Dividend 0/2
No dividends from the company in the past three years raises doubts about its profitability for shareholders.
Buffet Intrinsic Value 0/1
Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
TME Pharma N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It al…
Full company profileTME Pharma N.V. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TME Pharma N.V. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 83.0K | 234K | 0.00 | 154.00 | 35.00 | 33.0K | 0.00 | 17.0K | 19.0K | 0.00 | - |
| Gross Profit | -1.38M | -725K | -982K | -1.03M | -63.0K | -66.0K | -92.0K | -127K | -78.0K | -8.00K | -8.00K |
| Operating Income | -8.60M | -4.73M | -4.37M | -3.95M | -5.77M | -13.3M | -12.0M | -5.62M | -5.28M | -2.91M | -896K |
| EBITDA | -8.44M | -3.68M | -3.96M | -810K | -5.29M | -12.9M | -11.6M | -5.07M | -5.17M | -2.90M | -888K |
| Net Income | -10.7M | -5.39M | -10.7M | -861K | -10.4M | -14.5M | -15.1M | -6.74M | -5.72M | -3.29M | -2.03M |
| EPS | -671 | -254 | -270 | -6.99 | -29 | -22 | -13 | -1.34 | -0.21 | -0.03 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 2.87M | 929K | 4.52M | 1.73M | 10.7M | 9.77M | 5.24M | 2.49M | 3.41M | 2.14M | 1.18M |
| Total Liabilities | 5.35M | 4.85M | 7.13M | 3.59M | 2.96M | 5.27M | 6.51M | 2.79M | 1.79M | 3.72M | 3.79M |
| Shareholders' Equity | -2.48M | -3.91M | -2.60M | -1.84M | 7.71M | 4.52M | -1.27M | -294K | 1.61M | -1.58M | -2.61M |
| Cash & Short-term Investments | 2.21M | 690K | 4.32M | 1.39M | 10.3M | 9.48M | 4.63M | 2.25M | 3.25M | 2.02M | 1.03M |
| Total Debt | 2.94M | 2.61M | 4.79M | 129K | 107K | 2.44M | 4.09M | 1.17M | 56.0K | 2.39M | 2.89M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.99M | -4.24M | -4.00M | -4.29M | -5.22M | -12.4M | -12.1M | -5.64M | -4.63M | -3.42M | -3.30M |
| Capital Expenditure | 21.0K | 2.00K | 9.00K | 16.0K | 39.0K | 14.0K | 21.0K | 19.0K | 16.0K | 0.00 | 0.00 |
| Free Cash Flow | -9.01M | -4.24M | -4.01M | -4.30M | -5.26M | -12.4M | -12.2M | -5.65M | -4.65M | -3.42M | -3.30M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -135.0% | -320.1% | - | - | -354.5% | - | - |
| ROA | -374.6% | -579.7% | -237.6% | -49.7% | -97.7% | -148.0% | -288.7% | -270.4% | -168.0% | -153.6% | -171.7% |
| Net Profit Margin | -12,948.2% | -2,301.3% | - | -559,090.9% | -29,728,571.4% | -43,793.9% | - | -39,623.5% | -30,115.8% | - | - |
| Debt to Equity | - | - | - | - | 0.01x | 0.54x | - | - | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TME Pharma N.V. dividends
TME Pharma N.V. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jul 28, 2022.
Who owns TME Pharma N.V.
- Insiders 0.00%
- Institutions 3.88%
- Public & others 96.12%
- Shares outstanding 96.7M
- Free float 91.5M
TME Pharma N.V. company profile
- Company name
- TME Pharma N.V.
- Ticker
- ALTME.PA
- ISIN
- NL0015000YE1
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- Max-Dohrn-Strasse 8-10, Berlin, Germany, 10589
- Phone
- 49 30 16637082 0
- Website
- tmepharma.com
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
TME Pharma N.V. management
3- Mr. Diede Mink van den OudenCEO & Member of Management Board · born 1981
- Dr. Aram Mangasarian M.B.A., Ph.D.Chief Scientific Officer & Member of Management Board · born 1970
- Dr. Jarl Ulf Jungnelius M.D., Ph.D.Chief Medical Officer & Member of Management Board · born 1951